期刊
BIOCHEMICAL SOCIETY TRANSACTIONS
卷 39, 期 -, 页码 492-494出版社
PORTLAND PRESS LTD
DOI: 10.1042/BST0390492
关键词
ATP-competitive inhibitor; hypoxia-inducible factor (HIF); mammalian target of rapamycin (mTOR); rapalogue; renal cell carcinoma (RCC)
Targeting mTOR (mammalian target of rapamycin) is an effective approach in the treatment of advanced RCC (renal cell carcinoma). Rapamycin-like drugs (rapalogues) have shown clinical activities and have been approved for the treatment of RCC. Recently, with the development of ATP-competitive inhibitors of mTOR, therapies targeting mTOR have entered a new era. Here, we discuss the biological relevance of blocking mTOR in RCC and review the mechanisms of action of rapalogues in RCC. We also advance some perspectives on the use of ATP-competitive inhibitors of mTOR in RCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据